Advanced Miniature In-Line Blood Gas Analyzer Launched in Europe
|
By LabMedica International staff writers Posted on 31 Mar 2015 |

Image: The miniature Proxima Sensor is integrated into a patient’s arterial line to be used for directly monitoring blood gases and electrolytes over a 72 hour period as many times as required (Photo courtesy of Sphere Medical).

Image: The new Proxima in-line patient-dedicated point-of-care blood gas analyzer incorporates Proxima Sensor (in foreground) and dedicated bedside monitor (Photo courtesy of Sphere Medical).
A CE-marked patient-dedicated system, presented at ISICEM 2015, delivers point-of-care testing (POCT) by enabling critical care staff to obtain rapid and frequent laboratory-accurate arterial blood gas measurements without leaving the patient’s bedside, facilitating effective and timely clinical decisions.
Sphere Medical (Cambridge, UK) presented its Proxima System at the 35th International Symposium on Intensive Care and Emergency Medicine (ISICEM 2015; Brussels, Belgium, March 17-20, 2015) for launch in mainland Europe. Proxima revolutionizes conventional POCT as it is attached directly to the patient through their arterial line. The miniature Proxima Sensor, containing a range of biological sensors, sits in series in the arterial line with the blood pressure transducer. For the first time, blood gas results can be delivered, like blood pressure results, within the patient’s bed space.
Proxima is simple to use, enables closed blood sampling, and is operated via the touch-screen interface of its dedicated bedside monitor. Blood is withdrawn from the patient directly into the Proxima Sensor and a panel of analytes is measured. All blood is returned to the patient – promoting blood conservation and reducing the possibility of hospital acquired anemia and subsequent transfusions. The disposable sensor can be used for monitoring blood gases and electrolytes over a 72 hour period as many times as required.
Proxima has been fully evaluated and validated in a clinical setting. A recent observational method comparison study at Queen Elizabeth Hospital (Birmingham, UK) showed excellent agreement between Proxima and hospital standard benchtop blood gas analyzers, measuring various parameters of intensive care unit (ICU) patients with a range of clinical conditions, including trauma, head injury, post-surgical recovery, and sepsis.
Dr. Tom Clutton-Brock, senior lecturer, Anaesthesia and Intensive Care Medicine, University Hospital Birmingham, said, “Rapid return of data and swift response to changing blood gases is as essential in-patient care as the continual measurement of blood pressure. Fast feedback and response could have a real impact on efficiently stabilizing patients or weaning them from mechanical ventilation.” At ISICEM 2015 Dr. Clutton-Brock presented on “Bedside Blood Analysis,” discussing how frequent measurement of arterial blood samples is a key component in the effective management of critical care patients, particularly those who are unstable. At a poster session, Dr. Clutton-Brock and Dr. Jess Fox (Sphere Medical) discussed the excellent evaluation results of the Queen Elizabeth Hospital study.
Related Links:
Sphere Medical
35th International Symposium on Intensive Care and Emergency Medicine (ISICEM 2015)
Sphere Medical (Cambridge, UK) presented its Proxima System at the 35th International Symposium on Intensive Care and Emergency Medicine (ISICEM 2015; Brussels, Belgium, March 17-20, 2015) for launch in mainland Europe. Proxima revolutionizes conventional POCT as it is attached directly to the patient through their arterial line. The miniature Proxima Sensor, containing a range of biological sensors, sits in series in the arterial line with the blood pressure transducer. For the first time, blood gas results can be delivered, like blood pressure results, within the patient’s bed space.
Proxima is simple to use, enables closed blood sampling, and is operated via the touch-screen interface of its dedicated bedside monitor. Blood is withdrawn from the patient directly into the Proxima Sensor and a panel of analytes is measured. All blood is returned to the patient – promoting blood conservation and reducing the possibility of hospital acquired anemia and subsequent transfusions. The disposable sensor can be used for monitoring blood gases and electrolytes over a 72 hour period as many times as required.
Proxima has been fully evaluated and validated in a clinical setting. A recent observational method comparison study at Queen Elizabeth Hospital (Birmingham, UK) showed excellent agreement between Proxima and hospital standard benchtop blood gas analyzers, measuring various parameters of intensive care unit (ICU) patients with a range of clinical conditions, including trauma, head injury, post-surgical recovery, and sepsis.
Dr. Tom Clutton-Brock, senior lecturer, Anaesthesia and Intensive Care Medicine, University Hospital Birmingham, said, “Rapid return of data and swift response to changing blood gases is as essential in-patient care as the continual measurement of blood pressure. Fast feedback and response could have a real impact on efficiently stabilizing patients or weaning them from mechanical ventilation.” At ISICEM 2015 Dr. Clutton-Brock presented on “Bedside Blood Analysis,” discussing how frequent measurement of arterial blood samples is a key component in the effective management of critical care patients, particularly those who are unstable. At a poster session, Dr. Clutton-Brock and Dr. Jess Fox (Sphere Medical) discussed the excellent evaluation results of the Queen Elizabeth Hospital study.
Related Links:
Sphere Medical
35th International Symposium on Intensive Care and Emergency Medicine (ISICEM 2015)
Latest Hematology News
- Advanced CBC-Derived Indices Integrated into Hematology Platforms
- Blood Test Enables Early Detection of Multiple Myeloma Relapse
- Single Assay Enables Rapid HLA and ABO Genotyping for Transplant Matching
- Prognostic Biomarker Identified in Diffuse Large B-Cell Lymphoma
- Routine Blood Test Parameters Link Anemia to Cancer Risk and Mortality
- Prognostic Tool Guides Personalized Treatment in Rare Blood Cancer
- New Platelet Function Assay Enables Monitoring of Antiplatelet Therapy
- Open Multi-Omics Platform Identifies Prognostic Subtypes in Blood Cancers
- AI-Powered Digital Workflow Standardizes Bone Marrow Aspirate Morphology
- Rapid Cartridge-Based Test Aims to Expand Access to Hemoglobin Disorder Diagnosis
- New Guidelines Aim to Improve AL Amyloidosis Diagnosis
- Automated Hemostasis System Helps Labs of All Sizes Optimize Workflow
- Fast and Easy Test Could Revolutionize Blood Transfusions
- High-Sensitivity Blood Test Improves Assessment of Clotting Risk in Heart Disease Patients
- AI Algorithm Effectively Distinguishes Alpha Thalassemia Subtypes
- MRD Tests Could Predict Survival in Leukemia Patients
Channels
Molecular Diagnostics
view channel
Liquid Biopsy Biomarkers Distinguish Inflammatory Breast Cancer and Support Monitoring
Inflammatory breast cancer is among the most aggressive forms of breast malignancy and remains challenging to diagnose and monitor. Obtaining tumor tissue can be difficult, and standard genome and RNA... Read more
Blood Test Maps Tumor Microenvironment to Predict Immunotherapy Response
Immunotherapy has transformed cancer care, yet durable benefit remains limited to a subset of patients, and clinicians still lack reliable tools to predict response before treatment begins.... Read more
Multiplex Respiratory Panel Integrates Automated Extraction to Streamline High-Volume Testing
Respiratory infections drive heavy testing volumes in clinical laboratories, where accurate, timely results across multiple pathogens are essential. Many labs are seeking to streamline workflows and increase... Read moreHematology
view channel
Advanced CBC-Derived Indices Integrated into Hematology Platforms
Diatron, a STRATEC brand, has introduced six advanced hematological indices on its Aquila, Aquarius 3, and Abacus 5 hematology analyzers. The new Research Use Only (RUO) indices include Neutrophil-to-Lymphocyte... Read more
Blood Test Enables Early Detection of Multiple Myeloma Relapse
Bone marrow biopsies remain central to diagnosing and monitoring multiple myeloma, yet the procedure is painful, invasive, and often repeated over time. Older patients—who represent most new cases—can... Read moreImmunology
view channel
Point-of-Care Tests Could Expand Access to Mpox Diagnosis
Mpox outbreaks in non-endemic regions have underscored the need for rapid, accessible diagnostics to limit transmission. Polymerase chain reaction (PCR) remains the clinical reference, yet it depends on... Read more
T-Cell Senescence Profiling May Predict CAR T Responses
Chimeric antigen receptor (CAR) T-cell therapy can deliver striking, durable remissions, yet many patients experience minimal or no benefit. The quality of patient-derived cytotoxic T lymphocytes used... Read moreMicrobiology
view channel
Rapid Antigen Biosensor Detects Active Tuberculosis in One Hour
Tuberculosis remains a major global health challenge and continues to drive significant morbidity and mortality. The World Health Organization’s 2024 global report cites it as the leading cause of death... Read more
Oral–Gut Microbiome Signatures Identify Early Gastric Cancer
Early detection of gastric cancer could be advanced by scalable screening strategies using minimally invasive sampling. Saliva collection is noninvasive and cost-effective, supporting wider adoption... Read morePathology
view channel
FDA Clears AI Digital Pathology Tool for Breast Cancer Risk Stratification
Risk assessment at diagnosis is central to guiding therapy for early-stage, hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) invasive breast cancer, where overtreatment... Read more
New AI Tool Reveals Hidden Genetic Signals in Routine H&E Slides
Pathologists worldwide rely on hematoxylin and eosin (H&E) slides to examine tissue architecture, yet these stains do not reveal the underlying molecular activity that often drives disease.... Read moreTechnology
view channel
Tumor-on-a-Chip Platform Models Pancreatic Cancer Treatment Response
Pancreatic cancer remains one of the hardest malignancies to treat because tumors are embedded within a dense microenvironment that shapes growth and therapy response. Standard laboratory models often... Read more
New Platform Captures Extracellular Vesicles for Early Cancer Detection
Early diagnosis remains the most effective way to reduce cancer mortality, yet many screening tools miss disease at its earliest stages. Biomarkers shed by tumors into blood and other fluids can be scarce... Read moreIndustry
view channel
Roche to Acquire PathAI for Up to $1.05 Billion to Strengthen AI Diagnostics Portfolio
Roche has entered into a definitive merger agreement to acquire PathAI, a company focused on digital pathology and artificial intelligence for pathology laboratories and the biopharma industry.... Read more








